The goal of this study is to analyze the effects of enavogliflozin on heart function and coronary microvascular function in obese patients compared to a placebo, and to evaluate the improvement in cardiopulmonary exercise capacity in these patients.
None
Left ventricular ejection fraction (LVEF) < 50%
History of coronary artery disease, or patients who have undergone coronary artery intervention or coronary artery bypass grafting.
Patients with suspected obstructive coronary artery disease, including those with chest pain and positive stress test results (e.g., exercise treadmill test, dobutamine stress echocardiography, myocardial perfusion imaging).
Second-degree or higher atrioventricular block, symptomatic bradycardia, sick sinus syndrome, or Wolff-Parkinson-White syndrome.
Korea University Anam Hospital
Lead sponsor
Daewoong Pharmaceutical Co. LTD.
Collaborator